Indeed, a series of important clinical trials, initiated by the landmark studies EMPA-REG OUTCOME (with the sodium-glucose cotransporter-2 inhibitor (SGLT2i) empagliflozin) and LEADER (with the glucagon-like peptide-1 receptor (GLP-1RA) agonist liraglutide) demonstrated an unequivocal benefit in terms of cardio-vascular and renal event risk reduction and the prolonged survival of high-risk patients with different stages of diabetic kidney disease (DKD) [1,2]. The gene discussed is GLP1R; the disease is diabetic kidney disease.